[Use of an opioid antagonist naloxone and the agonist-antagonist nalbuphine during the awakening period to eliminate depressive effects of fentanyl].
Buniatian
A A
AA
Trekova
N A
NA
Ter-Mikaelian
D K
DK
Mierbekov
E M
EM
Asmangulian
E T
ET
D000293:Adolescent; D000328:Adult; D000368:Aged; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General; D002648:Child; D002675:Child, Preschool; D003864:Depression, Chemical; D004066:Digestive System Diseases / Q000601:surgery; D005283:Fentanyl / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D006331:Heart Diseases / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009266:Nalbuphine / Q000008:administration & dosage*; D009270:Naloxone / Q000008:administration & dosage*; D011182:Postoperative Care; D012131:Respiratory Insufficiency / Q000139:chemically induced / Q000517:prevention & control*; D014947:Wounds and Injuries / Q000601:surgery
D009270:Naloxone; D009266:Nalbuphine; D005283:Fentanyl
Primenenie opioidnogo antagonista naloksona i agonista-antagonista nalbufina v period probuzhdeniia dlia ustraneniia depressivnykh éffektov fentanila.